key: cord-1044564-xzy98hm3 authors: Gray, Kathryn J.; Bordt, Evan A.; Atyeo, Caroline; Deriso, Elizabeth; Akinwunmi, Babatunde; Young, Nicola; Medina Baez, Aranxta; Shook, Lydia L.; Cvrk, Dana; James, Kaitlyn; De Guzman, Rose; Brigida, Sara; Diouf, Khady; Goldfarb, Ilona; Bebell, Lisa M.; Yonker, Lael M.; Fasano, Alessio; Rabi, S. Alireza; Elovitz, Michal A.; Alter, Galit; Edlow, Andrea G. title: COVID-19 vaccine response in pregnant and lactating women: a cohort study date: 2021-03-26 journal: Am J Obstet Gynecol DOI: 10.1016/j.ajog.2021.03.023 sha: 8f537c46fa547a57bb72735f708725b6e78cd226 doc_id: 1044564 cord_uid: xzy98hm3 Background Pregnant and lactating women were excluded from initial COVID-19 vaccine trials; thus, data to guide vaccine decision-making are lacking. Objectives To evaluate the immunogenicity and reactogenicity of COVID-19 mRNA vaccination in pregnant and lactating women compared to: (1) non-pregnant controls and (2) natural COVID-19 infection in pregnancy. Study Design 131 reproductive-age vaccine recipients (84 pregnant, 31 lactating, and 16 non-pregnant) were enrolled in a prospective cohort study at two academic medical centers. Titers of SARS-CoV-2 Spike and RBD IgG, IgA and IgM were quantified in participant sera (N=131) and breastmilk (N=31) at baseline, second vaccine dose, 2-6 weeks post second vaccine, and at delivery by Luminex. Umbilical cord sera (N=10) titers were assessed at delivery. Titers were compared to those of pregnant women 4-12 weeks from natural infection (N=37) by ELISA. A pseudovirus neutralization assay was used to quantify neutralizing antibody titers for the subset of women who delivered during the study period. Post-vaccination symptoms were assessed via questionnaire. Kruskal-Wallis tests and a mixed effects model, with correction for multiple comparisons, were used to assess differences between groups. Results Vaccine-induced antibody titers were equivalent in pregnant and lactating compared to non-pregnant women (median [IQR] 5.59 [4.68-5.89] pregnant, 5.74 [5.06-6.22] lactating, 5.62 [4.77-5.98] non-pregnant, p = 0.24). All titers were significantly higher than those induced by SARS-CoV-2 infection during pregnancy (p < 0.0001). Vaccine-generated antibodies were present in all umbilical cord blood and breastmilk samples. Neutralizing antibody titers were lower in umbilical cord compared to maternal sera, although this finding did not achieve statistical significance (median [IQR] 104.7 [61.2-188.2] maternal sera, 52.3 [11.7-69.6] cord sera, p=0.05). The second vaccine dose (boost dose) increased SARS-CoV-2-specific IgG, but not IgA, in maternal blood and breastmilk. No differences were noted in reactogenicity across the groups. Conclusions COVID-19 mRNA vaccines generated robust humoral immunity in pregnant and lactating women, with immunogenicity and reactogenicity similar to that observed in non-pregnant women. Vaccine-induced immune responses were significantly greater than the response to natural infection. Immune transfer to neonates occurred via placenta and breastmilk. SARS-CoV-2 infection during pregnancy (p < 0.0001). Vaccine-generated antibodies were 108 present in all umbilical cord blood and breastmilk samples. Neutralizing antibody titers were 109 lower in umbilical cord compared to maternal sera, although this finding did not achieve provider counseling is lacking [9] [10] [11] . Specifically, given the novelty of the first emergency 141 approved COVID-19 vaccines, both of which utilize mRNA to deliver SARS-CoV-2 Spike to 142 educate the immune system 12,13 , it remains unclear whether this novel vaccine approach will 143 drive immunity in the context of pregnancy, and whether antibodies will be transferred 144 efficiently to neonates via the cord and breastmilk. Here, vaccine-induced immunity was profiled Luminex assay was used to determine relative titer of antigen-specific isotypes and subclasses 182 using the following antigens: SARS-CoV-2 Receptor Binding Domain (RBD), S1, and S2 (all The lowest final dilution of each serum sample is therefore 15-fold. The cells were incubated at 199 37 o C for 48 hours, and the RFP was quantified using the flow cytometer (BD Accuri™ C6). Additional details about this assay may be found in the Supplemental Methods. Delivery information for the 13 pregnant participants who delivered during the study period is 246 detailed in Table 2 . All 13 were vaccinated in the third trimester. Three women delivered at 247 hospitals other than the study sites and cord blood samples were not available. Of the ten 248 umbilical cord blood samples available for analysis, 9/10 mothers had received both vaccine Table 2 . The maternal vaccine response 253 IgM, IgG, and IgA responses to the Spike (S), receptor binding domain (RBD), S1-segment of S, 254 and S2-segment of S were measured. A significant rise in all isotypes across all antigens was 255 observed from V0 to V1, with a further rise in IgG levels from V1 to V2 in both the pregnant and 256 lactating groups (Fig 1A-D and Supplemental Fig 1) . Spike titers rose more rapidly than RBD-257 titers after the first (V1/prime timepoint) and second (V2/boost timepoint) vaccine dose, but the 258 J o u r n a l P r e -p r o o f magnitude of the response did not differ across pregnant or lactating women. In contrast to IgG 259 responses, IgM and IgA responses were induced robustly after the prime, and were poorly 260 induced after boosting, across all groups (Fig 1C and D) . Higher S-and RBD-specific IgA IgG for pregnant, lactating, and non-pregnant women (Fig 1E and Supplemental Fig 1C) . 265 Vaccine-induced maternal antibody titers in sera did not differ by trimester of vaccination (Fig 1) . However, whether these antibodies were transferred efficiently to infants remained 273 unclear. Thus, we next examined the levels of antibodies in breastmilk of lactating mothers ( Fig 274 2 A-C) . Robust induction of IgG, IgA, and IgM were observed following the prime and boost. 275 Interestingly, IgA and IgM levels did not increase with boosting, in synchrony with a minimal 276 boost in these isotypes in serum (Fig 1C/D and Supplemental Fig 1A-E) . However, a boost in 277 breastmilk IgG levels was observed (Fig 2A) , concomitant with the boost observed 278 systemically/in maternal serum (Fig 1A) . IgG1 RBD rose significantly from V0 to V2 (3.44 to 279 3.50, p = 0.002) but not V0 to V1 (3.44 to 3.45, p=0.7) in breastmilk, and there was no 280 significant rise in anti-RBD IgA or IgM in breastmilk after either dose (Supplemental Fig 4) . Table 2 ). Within the pregnant women, medical comorbidities were not 304 significantly associated with maternal serum antibody titers, although there were relatively few 305 medical comorbidities in this group. Update: Characteristics of Symptomatic Women 409 of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy 410 SARS-CoV-2 vaccines in development SARS-CoV-2 Vaccines Involving Pregnant Individuals in Clinical Research 416 on COVID-19 Vaccines Inclusion of Pregnant and Lactating Persons in COVID-19 Vaccination Efforts The need for inclusion of pregnant women in 422 COVID-19 vaccine trials COVID-19 vaccine testing in pregnant females is necessary Balancing risks: making decisions for maternal treatment without data 426 on fetal safety The coronavirus disease 2019 vaccine in pregnancy: 429 risks, benefits, and recommendations -2 vaccine: an ethics-based framework for shared decision-making COVID-19 vaccine BNT162b1 elicits human 435 antibody and TH1 T cell responses An mRNA Vaccine against SARS-CoV-2 -437 Compromised SARS-CoV-2-specific placental 439 antibody transfer Transplacental Antibody Transfer, and Placental Pathology in Pregnancies 442 During the COVID-19 Pandemic Factors Affecting the FcRn-Mediated Transplacental 446 Transfer of Antibodies and Implications for Vaccination in Pregnancy The Impact of IgG transplacental 449 transfer on early life immunity HIV-specific functional antibody responses in breast 451 milk mirror those in plasma and are primarily mediated by IgG antibodies Correlate of Protection Against Respiratory Syncytial Virus Acute Respiratory Illness Impact of pertussis-specific IgA, IgM, and IgG antibodies in mother's own breast milk and 458 donor breast milk during preterm infant digestion. Pediatric Research Characterization of SARS-CoV-2 RNA Neutralizing Capacity in Milk Produced by Women with COVID-19 V-safe after vaccination health checker